8. Brolucizumab

Novartis headquarters
Novartis has been staffing up in key regions ahead of the brolucizumab launch, an executive told FiercePharma earlier this year. (Novartis)

Generic name: brolucizumab
Company: Novartis
Disease: wet age-related macular degeneration
2024 sales estimate: $1.38 billion 

Regeneron and Roche are already duking it out in wet age-related macular degeneration with Eylea and Lucentis, and they may have more company later this year. 

In April, Novartis’ brolucizumab scored an FDA priority review, setting the drug up for a possible U.S. nod in October. Novartis laid out a priority review voucher to win the quick review, showing just how enthusiastic the company is about the prospective launch.

As further evidence that Novartis is intent on the impending showdown, it's been staffing up in key regions ahead of the FDA decision, an executive told FiercePharma earlier this year. The company submitted two phase 3 trials called Hawk and Harrier to support its FDA application.  

RELATED: Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis 

EvaluatePharma has predicted the drug will generate $1.38 billion by 2024.  

But Roche and Regeneron aren’t just sitting around waiting for the Novartis’ nod. Roche has its own next-generation AMD contender in faricimab, a phase 3 prospect. For its part, Regeneron recently scored a diabetic retinopathy approval for Eylea.  

8. Brolucizumab

Suggested Articles

Roche’s Tecentriq couldn’t repeat its TNBC success in tandem with chemo med paclitaxel in previously untreated metastatic patients

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.